A Kaplan-Meier model compared median PFS and OS between cohorts. Patients were dichotomized based on AG MRD status (negative vs positive). Additional BM MRD results were also available at 1- and 2-years post-AHCT for most patients. BM MRD status was assessed post-induction/pre-SCC and at 3-months post-AHCT. AG MRD status was assessed in peripheral blood at the time of stem cell collection (SCC). Methods: This study included 119 NDMM patients with prospectively collected BM and AG MRD results by NGF who underwent stem cell collection and up-front AHCT at our institution between Sept 2017 and Feb 2020. To address this, we examined MM contamination of AG by next-generation flow cytometry (NGF) to determine the predictive value of AG MRD status on outcomes after AHCT. However, it is unclear whether stem cell autograft (AG) contamination with myeloma cells and/or their precursors contributes to relapse after AHCT. Contemporary induction regimens generate deeper responses, with higher rates of minimal residual disease (MRD) negativity in the bone marrow (BM) leading to improved progression-free survival (PFS) and overall survival (OS). Chung, MD, PhD 4,6, Gaurav Gupta 13 *, Elena Maryamchik 13 *, Evangelos Ntrivalas 14 * and Mikhail Roshal, MD 15ġthe Sloan Kettering Institute for Cancer Research, New York, NYĢDepartment of Epidemiology-Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NYģDepartment of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NYĤDepartment of Medicine, Weill Cornell Medical College, New York, NYĥMemorial Sloan Kettering Cancer Center, New York, NYĦAdult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NYħAdult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center/New York, New York, NYĨDepartment of Medicine, Adult Bone Marrow Transplant Service, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NYĩMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NYġ0Weill Cornell Medical College, New York, NYġ2Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NYġ3Transfusion Medicine and Cell Therapy, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New Yorkġ4Cellular Immunology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New Yorkġ5Department of Pathology and Laboratory Medicine, Hematopathology Service, Memorial Sloan Kettering Cancer Center, New York, NYīackground: Autologous hematopoietic stem cell transplantation (AHCT) in the up-front setting is the standard-of-care for newly diagnosed multiple myeloma (NDMM). Giralt, MD, FACP, FASTCT 4,12 *, David J. Shah, MD 4,8 *, Hani Hassoun, MD 9, Malin Hultcrantz, MD, PhD 9, Neha Korde, MD 9, Alexander M Lesokhin, MD 5,10, Sham Mailankody, MBBS 5, Urvi A Shah, MD 9, Carlyn Tan, MD 9, Saad Usmani, MD 11, Sergio A. Dahi, MD 4,5, Heather Landau, MD 4,6, Oscar B Lahoud, MD 6, Michael Scordo, MD 4,7, Gunjan L. Noriko Nishimura, MD, PhD 1 *, Samantha Brown, MS 2 *, Sean M.
0 Comments
Leave a Reply. |